236 results on '"Michel, Loren"'
Search Results
2. A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer
3. Post-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity
4. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
5. Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers
6. A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma
7. Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma
8. Abstract PO-072: Durvalumab in combination with radioactive iodine in recurrent/metastatic thyroid cancers: Update on clinical and correlative analyses
9. International consensus statement on allergy and rhinology: Sinonasal tumors
10. Complete Loss of the Tumor Suppressor MAD2 Causes Premature Cyclin B Degradation and Mitotic Failure in Human Somatic Cells
11. LookUpTrials: Assessment of an artificial intelligence-powered mobile application to engage oncology providers in clinical trials.
12. Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer
13. Supplementary Figures 1-4, Table 1 from Loss of Trop2 Promotes Carcinogenesis and Features of Epithelial to Mesenchymal Transition in Squamous Cell Carcinoma
14. Supplementary Figure 9 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
15. Supplementary Figure 5 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
16. Supplementary Tables from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
17. Supplementary Figure 1 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
18. Supplementary Data from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
19. Supplementary Figure 8 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
20. Supplementary Figure 6 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
21. Supplementary Appendix from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
22. Supplementary Figure 3 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
23. Supplementary Figure Legends 1-4 from Synthetic Lethality through Combined Notch–Epidermal Growth Factor Receptor Pathway Inhibition in Basal-Like Breast Cancer
24. Data from RNA Helicase DDX5 Is a p53-Independent Target of ARF That Participates in Ribosome Biogenesis
25. Supplementary Figure 4 from Synthetic Lethality through Combined Notch–Epidermal Growth Factor Receptor Pathway Inhibition in Basal-Like Breast Cancer
26. Supplementary Figure 1 from Synthetic Lethality through Combined Notch–Epidermal Growth Factor Receptor Pathway Inhibition in Basal-Like Breast Cancer
27. Supplementary Figure 3 from Synthetic Lethality through Combined Notch–Epidermal Growth Factor Receptor Pathway Inhibition in Basal-Like Breast Cancer
28. Supplementary Figure 1 from RNA Helicase DDX5 Is a p53-Independent Target of ARF That Participates in Ribosome Biogenesis
29. Supplementary Figure 2 from RNA Helicase DDX5 Is a p53-Independent Target of ARF That Participates in Ribosome Biogenesis
30. Data from Synthetic Lethality through Combined Notch–Epidermal Growth Factor Receptor Pathway Inhibition in Basal-Like Breast Cancer
31. Supplementary Figure 2 from Synthetic Lethality through Combined Notch–Epidermal Growth Factor Receptor Pathway Inhibition in Basal-Like Breast Cancer
32. Supplementary Figure 3 from RNA Helicase DDX5 Is a p53-Independent Target of ARF That Participates in Ribosome Biogenesis
33. Supplementary Table 1 from RNA Helicase DDX5 Is a p53-Independent Target of ARF That Participates in Ribosome Biogenesis
34. Supplementary Methods from RNA Helicase DDX5 Is a p53-Independent Target of ARF That Participates in Ribosome Biogenesis
35. nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma
36. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
37. Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma
38. Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma
39. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy
40. Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck
41. Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma
42. A pilot study of trametinib in combination with paclitaxel in the treatment of anaplastic thyroid cancer.
43. A pilot study of neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab in patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC).
44. Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo
45. Treatment Outcomes for T4 Oropharyngeal Squamous Cell Carcinoma
46. Abstract CT207: Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors
47. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy
48. A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic salivary gland cancers (R/M SGCs).
49. The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer.
50. Postoperative PET/CT for detection of early recurrence (ER) after surgery for squamous cell carcinomas (SCC) of the oral cavity (OC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.